{"name":"Acumen Pharmaceuticals","slug":"acumen-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":104885000,"netIncome":-121335000,"cash":53989000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxORGF3TG1rYkRaTVZWYjNoZW04YzFSZ0JmVzBlaGZkTWIyb1ZOclhzaXBJRUVtcEladlRZUGdvbUR1ZzlnYzZmR1d4WHJnOGRJd3hkYUdxTmJWa0JIWXoxeWxzeFlKaWwxanpiTFBVLUxzQWR0dWtBN0h2aVh4b3l1VFFsRmVuR0Fsakpn?oc=5","date":"2026-03-17","type":"pipeline","source":"Yahoo Finance","summary":"Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026 - Yahoo Finance","headline":"Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPakJIU2o0LWlPVVNhZXV4cDV4MFY0MjZ0eGlRY19kZlp0YVExZzl5MXkwd25BdlpDaWJhTmJURGR4cGJXaGZFUmNCaVcxRDRPcHVHYUJRWmpUQW5JRWNCZHp0dHE2djJSUU9XRVZueWpuN0NEN0JRbnYyLTVsY2dsbF8xS1R1OXBGcnZ6dF9pbnQ5WWQwdWd3YUV1QjNlZVZKRUlZanpTeTVBZU16amVmWkt1MlhzZDZyc1FZLXhzX3VQS09F?oc=5","date":"2026-03-03","type":"pipeline","source":"Investing.com","summary":"Acumen Pharma chief legal officer Meisner sells $28k in shares - Investing.com","headline":"Acumen Pharma chief legal officer Meisner sells $28k in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSHI3ZFhaVmM3MlhQY2ttZFZYck9Xd1hhcmRZd21TVzNMTTdrUkM5YTEyQ00wVkp5QkJrNWg5R2NMNGZwRW53TnNiZkVFUWRCYTNYV3lVTG8xMnM2X0tjUFBaUjNQNHZaejFnUmpEZVpPRE80Z3J1WGpuNFF1M1A0Z1JTYmZHWUlXLTVBdVhaVFRmVVIyUVc2R3RjV3NiNUtJbjBTVjhaOE10cDl4UHdBYS10c2hMOUJWR1FELXhPNklVdw?oc=5","date":"2026-01-28","type":"pipeline","source":"Investing.com","summary":"Acumen Pharma CLO sells $53k in shares after option exercise - Investing.com","headline":"Acumen Pharma CLO sells $53k in shares after option exercise","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-27","type":"trial","source":"simplywall.st","summary":"Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative? - simplywall.st","headline":"Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOamJzS3VuT24xbUhuQTJNaGM4UWY2ME5YdTlIZmtCcEI1cXpsYWVhNThJc0ptaHhLcGpZWTVUMXl4ZzJQdk5pQWNDcHMtdE0yVVpIRnBQeVZycjVJWTNCV2RJSWhtSUVET3o1RG1Sc2F6VnlwaE1QWWdnb0djVVh0TUxuakY1OHo5dGc?oc=5","date":"2025-11-28","type":"pipeline","source":"Yahoo Finance","summary":"Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance","headline":"Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxONlFLbnNHbFZ3TkJrc2YtZ3FsRThMNW1aaHp1d1U0SVVGV09ZLWRXa1BmYVkzSks5SVVaMlAyMnROb0tFeXhLQmFoME15SFcwd1FyMzdZSHRzQXhNZGJqSGE4NDI1Q3loODl5emQzWnlMNmExcTQ1QWtYOGlzekY1d0R0VGV1THJjQTlzc2Z3V0xQMVE1d1Y3bmdrWjN2Um5OQUEzOUhZcXFGOHczVlIwVll5UkVtb2hvY2UtaFlOS3M?oc=5","date":"2025-11-17","type":"pipeline","source":"Fierce Biotech","summary":"Breaking Barriers and Crossing Borders: JCR Pharma Launches into Next 50 Years of Innovation with Global Alliances - Fierce Biotech","headline":"Breaking Barriers and Crossing Borders: JCR Pharma Launches into Next 50 Years of Innovation with Global Alliances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOSDVlWXJ1UHFDdzMyQ0pQeGVvOUk3eUJ5aXJxTkp0Ti10WjhuZHV5MzhDWWdQSTNZUkVPckY0cGFxeHhEbTQ1Q1JtMk1LZS0wVE93TkhFRmNFQU9JLXpGaEdwYkFUWDh2ODk2X2Y2b0EwZ3A5RUVCZWpidWl6T2QzOXVyaVJtRjNzLVU4eWZGM1d2czdQNVhzVl9sbTFXajR5?oc=5","date":"2025-07-16","type":"pipeline","source":"The Pharma Letter","summary":"JCR Pharma links up with Acumen on Alzheimer’s research - The Pharma Letter","headline":"JCR Pharma links up with Acumen on Alzheimer’s research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOMDJZS2o5TGRmSlRGRDFjaGxtbThuUWI0WmZhOUstZGdJRGlxSHBkOVZ0aWxLdFYwXzRhWUw5Wk85Q1RoV2V0aU9hNUJ4T0lvMEJBd2NvUndGSGVwYkkwZEUwdzB3S0ptb0dSVWdTSVZOc25tVWtzRF90eDhqTHB5UDBtZDE3d1VBM3QyR3lrNzd6UHpUZnYyYlRqUElycExNb0E?oc=5","date":"2025-07-15","type":"deal","source":"Fierce Biotech","summary":"Acumen taps JCR’s blood-brain barrier tech for $555M Alzheimer’s deal - Fierce Biotech","headline":"Acumen taps JCR’s blood-brain barrier tech for $555M Alzheimer’s deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFByN0dVYkdxQ3hJUkktZUk4OFRBZ21hVXJnY2lJWU9Na3gzeDRNRHVZZHdFQmpuRlRHd2VLc0hJSTcxMmppSHZuTmdYc2dvQThNMVdj?oc=5","date":"2025-07-15","type":"pipeline","source":"FirstWord Pharma","summary":"JCR, Acumen join forces to develop brain-penetrant Alzheimer's therapeutic - FirstWord Pharma","headline":"JCR, Acumen join forces to develop brain-penetrant Alzheimer's therapeutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxQT0pEZkxiU3RVdGtubnRuM0RVNzZxZTRxaDFIOFVUTGFLbHNSUUF4M2xCQk1vQTdaSmFlY2VwdU81ckdGcmtxUTZhel9NV0IySHV2TFNha1N4RG13eGRjQl9KYllFbWdYWW1kZmFWY2ZEVXpCWm5qQktRMi0wdGd6NFhKM1NZbU95UjEwa2ozOXd6dkFmM1JHT0NiVjFhdWVmRk5tYks4NnJORGh6RklKWm03bjY0eDN6QTNldU85NkNwMzBoYjd4UzFVX0poOHQ2cUVsLVgyOEJZMWc1MzFGWktIZGxmQ2ptUEFFNlV1ZkZ5NFNsVTVmZDFoN2h0TWNDR0gzS2lJeXZOOExoZ3o3cDhRaC1LZVpMU1FhRm00YlRQaS11akpVWG5RTDVtakVFTE43RHVtTlA?oc=5","date":"2025-07-15","type":"deal","source":"Business Wire","summary":"JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire","headline":"JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enable","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNXzZXWEt1dmJOQjFSX2I3NHlocHdrVGNkX3lLSWJVS2FwZXVYWXdKWC1RcV9WVmxwYWxyX0wyRmg2YzBCT3Mxa1djdHExWU9zQjFYTktfRVo0S3ZMZWV2cmlFbFRKMTlhVW5UZDhHVS1yTkRxdHRNQjhXVlNmMllpQm5R?oc=5","date":"2025-03-27","type":"trial","source":"Clinical Trials Arena","summary":"Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s - Clinical Trials Arena","headline":"Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPYlZ6UE1Renp5V1Rtd0ZacDZhSTBxcGoyZWtaUmpYbEhVOFlxSGxDaEdiV0c4RXJJbVpScDdpSENxclpWUS1Oa3ZuZkdsOFNXZVVhblNrX3Uzeld0TkxmZFFtUFN3d1pyMW9zVTZsYjhKUExGYVJNemNEejFqWkRTSVFVY1hWUmhXSXJNUFc3cVRlY1J3ekVZdnpUbm9xMXpxTUEyMExkRmNWWE9Ianc?oc=5","date":"2024-11-01","type":"trial","source":"NeurologyLive","summary":"Acumen Pharmaceuticals’ Phase 2 Advancements in Alzheimer Disease Screening: Todd Feaster, PsyD - NeurologyLive","headline":"Acumen Pharmaceuticals’ Phase 2 Advancements in Alzheimer Disease Screening: Todd Feaster, PsyD","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":104885000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-121335000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":53989000,"cashHistory":[],"totalAssets":122833000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}